Abstract
Microangiopathic hemolytic anemia (MAHA) refers to nonimmune hemolysis resulting from the intravascular fragmentation of red blood cells. The etiology of such disorders can range from primary thrombotic microangiopathic syndromes (TMA) to various systemic conditions, posing a diagnostic challenge. Prompt identification requires a sharp clinical assessment to improve outcomes.
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Recommended Citation
Takla A, Vachon G, Hix j, Jadhav N. Mystery of MAHA: Hypertension’s Twist over Cancer’s Shadow. Advances in Clinical Medical Research and Healthcare Delivery. 2025; 5(2). doi: 10.53785/2769-2779.1272.
Included in
Hematology Commons, Internal Medicine Commons, Nephrology Commons